Tvardi Therapeutics (TVRD) Other Non-Current Liabilities (2023 - 2025)
Tvardi Therapeutics (TVRD) posted Other Non-Current Liabilities of $45.8 million for Q1 2025, up 3.09% sequentially from $44.4 million in Q4 2024, and up 19.4% YoY from $38.4 million in Q1 2024.
Tvardi Therapeutics (TVRD) Other Non-Current Liabilities (2023 - 2025) Analysis & Trends
Tvardi Therapeutics has reported Other Non-Current Liabilities for 3 years, with the latest figure at $45.8 million in Q1 2025.
- Quarterly Other Non-Current Liabilities rose 19.4% year-over-year to $45.8 million in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $45.8 million (up 19.4% YoY) and the FY2024 annual result came in at $44.4 million, up 19.87% from the prior year.
- Other Non-Current Liabilities rose to $45.8 million in Q1 2025 per TVRD's latest filing, from $44.4 million in the prior quarter.
- Over five years, Other Non-Current Liabilities peaked at $45.8 million in Q1 2025 and troughed at $37.1 million in Q4 2023.
- A 3-year average of $41.0 million and a median of $40.1 million in 2024 frame the typical range for Other Non-Current Liabilities.
- The sharpest annual moves came in 2024 and 2025: Other Non-Current Liabilities increased 19.87% in 2024, then grew 19.4% in 2025.
- Over 3 years, Other Non-Current Liabilities stood at $37.1 million in 2023, then rose by 19.87% to $44.4 million in 2024, then increased by 3.09% to $45.8 million in 2025.
- According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $45.8 million, $44.4 million, and $40.6 million for Q1 2025, Q4 2024, and Q3 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Tvardi Therapeutics | 17.36 Mn | 17.36 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 45.82 Mn |
| Dec 31, 2024 | 44.45 Mn |
| Sep 30, 2024 | 40.58 Mn |
| Jun 30, 2024 | 39.68 Mn |
| Mar 31, 2024 | 38.38 Mn |
| Dec 31, 2023 | 37.08 Mn |